menu
    • menu

    Company profile for Pfizer CentreOne

    Pfizer CentreOne -PSE
    News
    Expert Statement: Tom Wilson, Pfizer

    02 Sep 2024

    // CHEMANAGER

    Contract Pharma Talks with Rick Knight of Pfizer CentreOne

    30 Aug 2024

    // CONTRACT PHARMA

    Celebrating Excellence: Pfizer CentreOne wins the CDMO Leadership Awards 2024

    01 Apr 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Pfizer CentreOne

    Contact Supplier

    Website

    Biotech Digital Meet

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    speak-pharma/pfizer-centreone-is-distinct-from-other-cdmos-due-to-the-fact-that-we-are-embedded-within-pfizer-speakpharma-with-pfizer-centreone

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Pfizer CentreOne is a global CDMO and a leading supplier of Specialty APIs.

    Related CompaniesRelated Companies

    About

    Pfizer CentreOne® is an altogether different global contract development and manufacturing organization (CDMO), and a leading supplier of specialty APIs and intermediates.

    Backed by Pfizer resources, we’ve been delivering technical expertise, regulatory support and long-term supply for over 40 years. With 35+ sites across six continents, our expansive network allows us to securely and efficiently guide complex compounds from development through commercial manufacture.

    For more information, visit http://www.pfizercentreone.com

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Pfizer CentreOneUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Corporate Headquarters: 235 E. 42nd Street, New York, NY 10017
    Telephone
    Telephone
    +1 2698332296
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.pfizercentreone.com/api-finder
    Linkedin
    Linkedin
    https://www.linkedin.com/showcase/pfizer-centreone/
    youtube
    YouTube
    http://www.youtube.com/@PfizerCentreOne
    Twitter
    Twitter
    https://x.com/pfizer?s=20&t=eITNxWXVA6OT-5fIKV4rAA
    Contact Info
    Others

    https://goo.gl/y1jbJX

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    “Pfizer CentreOne is distinct from other CDMOs due to the fact that we are embedded within Pfizer”

    “Pfizer CentreOne is distinct from other CDMOs due to the fact that we are embedded within Pfizer”

    This week, SpeakPharma interviews Pfizer CentreOne’s Andrew Moore, General Manager, and Andrew Anderson, Lead, APIs and Intermediates, who talk about Pfizer CentreOne’s CDMO services, trends impacting the CDMO industry and their leading position as a supplier of specialty APIs and intermediates to pharma companies. The company, which was created five years back, when Pfizer CentreSource and Hospira One 2 One came together, has been growing at a healthy pace of 9 percent year-on-year, and wishes to launch 25 blockbusters by 2025. It’s been over five years since Pfizer CentreSource and Hospira One 2 One came together to create Pfizer CentreOne. Can you tell us what the journey has been like? Andrew Moore: Pfizer CentreOne has been successfully guiding customers’ products from development to commercial manufacture for over 40 years. We are a global provider of contract development and manufacturing services for small molecule APIs, large molecule biologics, oral solids and sterile injectables. In collaboration with our customers, we deliver these medicines to millions of patients all over the world. Our global team consists of around 70 colleagues who bring a wealth of scientific, manufacturing, and commercial expertise. Our network includes over 35 Pfizer sites across six continents with expertise to deliver technical guidance, regulatory support, and reliable supply. Since 2015, we have worked rigorously to optimize the structure and operating model of Pfizer CentreOne. In 2019, Pfizer’s CentreOne delivered US$ 810 million in annual revenue with 9 percent growth year-on-year. We are a strong commercial entity poised to show solid financial results in 2020 as well.  Andrew Anderson: In addition to this, Pfizer CentreOne is a leading supplier of specialty APIs and intermediates. Our Kalamazoo, Michigan facility, is a center of excellence for API production and continues to lead the industry by investing in next-generation processes. Customers can access the same technical and manufacturing resources that Pfizer uses for its own branded medicines. They can count on Pfizer CentreOne to deliver reliable API supply of the highest quality and a trusting partnership built on transparent communication and timelines. This is more important than ever as the industry faces increasing supply chain vulnerabilities and API supply issues. What differentiates Pfizer CentreOne from other CDMOs? Andrew Moore: Without any doubt, I can say that Pfizer CentreOne is distinct from other CDMOs due to the fact that we are embedded within Pfizer. With over 170 years of experience, Pfizer has hundreds of products to its name, and its development, manufacturing, regulatory and commercial expertise is unrivaled. When customers partner with us, they benefit from Pfizer’s specialized expertise in core therapeutic areas, enabling them to get their products to patients in a more timely and efficient manner. We believe relationships and collaboration are key for mutual success. We recognize our partners’ patients as our own and our goal is to understand their needs. Pfizer’s legacy of bringing innovative products to market is not just our history, it’s our future. We wish to launch 25 blockbusters by 2025. Pfizer invests US$ 1 billion annually into its manufacturing network and operations and this sustained commitment to innovation and optimization positions Pfizer CentreOne as a highly competitive, technology leading CDMO. The final differentiating factor is our aspiration to be the partner of choice and our customer experience promise. Our goal is to be known not only for what and when we deliver, but also for how we deliver. What are the growth areas for Pfizer CentreOne? Tell us about the geographical spread of your clients? Andrew Moore: We are focused on growing our core technology platforms through offering end-to-end solutions that start with early stage clinical development and clinical manufacturing and grow into commercial production and lifecycle management. The earlier we can influence formulation and synthesis routes the more successful our customers’ products will be, which is always our first objective. We have a great reputation for our work from Phase II through approval and we believe now is the time to offer customers the benefit of our experience in earlier development phases. In terms of geographical expansion, we are focusing on growing our presence in Asia through our state-of-the-art biotechnology manufacturing site in Hangzhou.    Andrew Anderson: We also see a real opportunity to expand our API and intermediates customer base as the need for reliable API suppliers is greater than ever. Pfizer has a track record of delivering high quality API supply when customers need it most. As we have complete control over Pfizer’s own API supply from farm to factory, we are able to offer this reassurance to our customers.  Can you share details on Pfizer CentreOne’s new green-chemistry API manufacturing program? Andrew Anderson: The team in our largest manufacturing facility, located in Kalamazoo, Michigan, USA, developed Enviero progesterone, the first compound to be launched from Pfizer CentreOne’s green-chemistry program. The API is produced by a first-of-its-kind progesterone synthesis process that reduces waste, greenhouse gas emissions and the use of hazardous solvents. Developed during the last decade, this represents a step change in progesterone API synthesis. Manufactured via a proprietary biocatalytic process based on plant sterols, efficiency and sustainability results have been exceptional, including cutting the carbon footprint of the progesterone manufacturing process by more than 70 percent and eliminating the use of metal catalysts. What are some of the trends impacting CDMOs? What are some of the areas where Pfizer CentreOne will be investing in the coming years? Andrew Moore: We believe that there has never been a more dynamic market nor a greater role for pharma and commercial partners. As more companies, including small, mid-sized and large pharma, turn to CDMOs for bringing their products to market, the CDMO industry is vital to advancing pharma breakthroughs. This has influenced CDMOs to invest in acquisitions and alliances to stay ahead of pharma’s development curve. Despite the increasing dependency of the pharmaceutical industry on CDMOs, the classic needs for CDMO partners remain as before — scientific innovation, high-demand technical experience, and first-class capabilities. Customers appreciate CDMO partners who present quality systems that prevent excursions and warnings along with a proven commercial track record.  Emerging industry needs are demanding more agility and a culture of continuous improvement, with responsive infrastructure to permit flexible scale profiles — particularly important with high complexity oral solid dosages.  Pfizer CentreOne will continue to focus on playing a strategic role in the successful development and commercial manufacture of our customers’ products and on optimizing our delivery through digital technology and infrastructure investments. Guiding today’s drug strategies through close collaboration with our customers will enable us to overcome some of today’s and tomorrow’s toughest drug development challenges.  

    Impressions: 4750

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/pfizer-centreone-is-distinct-from-other-cdmos-due-to-the-fact-that-we-are-embedded-within-pfizer-speakpharma-with-pfizer-centreone

    #SpeakPharma With Pfizer CentreOne
    11 Nov 2020
    Share info Share

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2022

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-81876.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-82993.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-85472.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    OSD Campaign Assets Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-98687.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Sterile Injectables Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-99854.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Large Molecule Biologics

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-13988.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Sterile Injectables Development Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-53701.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Small Molecule APIs Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-57249.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Oral Solids Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-82133.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Ascoli Site Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-33204.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Newbridge Site Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-84299.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Kalamazoo Site Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-683.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Freiburg Site Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-33787.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Enviero ™ Progesterone

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-1649133770.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    General Capabilities Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-93836.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    PC1's Expertise in Gene & Cell Therapy

    read-more

      https://www.pharmacompass.com/pdf/party/content/pfizer-centreone-party-content-29734.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out